• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does Haemonetics' (HAE) Buyback-Funded Loss Quarter Hint at Shifting Earnings Quality Priorities?

    Simply Wall St·05/19/2026 00:43:14
    Listen to the news
    • In early May 2026, Haemonetics Corporation reported fourth-quarter sales of US$346.35 million but moved from a prior-year profit to a US$20.15 million net loss, while full-year sales slipped to US$1.33 billion and net income fell to US$97.31 million, alongside the completion of a US$175 million share buyback program.
    • The combination of weaker profitability despite higher quarterly sales and a sizeable reduction in shares outstanding raises important questions about how earnings quality, capital allocation, and future returns on invested capital align with earlier expectations for margin expansion and growth.
    • Next, we will examine how the swing to a quarterly net loss and lower full-year earnings may reshape Haemonetics’ investment narrative.

    Capitalize on the AI infrastructure supercycle with our selection of the 43 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

    Haemonetics Investment Narrative Recap

    To own Haemonetics today, you need to believe its plasma, TEG, and vascular closure franchises can sustain attractive returns despite recent earnings pressure. The swing to a fourth quarter loss and lower full year profit highlights that near term, the key catalyst is restoring margin momentum, while the biggest risk is that execution challenges in core U.S. products, especially VASCADE, keep profitability from recovering. This quarter’s results are material to how confident you feel about both.

    The completion of the US$175 million buyback program, which reduced the share count by 6.34%, is particularly relevant against weaker earnings, because it amplifies the importance of future profit growth to justify returning so much capital. At the same time, upcoming conference appearances may offer more color on how management intends to improve earnings quality, support plasma growth with NexSys and Persona PLUS, and address the concentrated product and U.S. exposure risks that now feel more immediate.

    Yet beneath the higher quarterly sales, the combination of a net loss, lower margins, and a reduced share count creates a risk investors should be aware of if...

    Read the full narrative on Haemonetics (it's free!)

    Haemonetics' narrative projects $1.5 billion revenue and $247.6 million earnings by 2029. This requires 5.3% yearly revenue growth and about a $72.2 million earnings increase from $175.4 million today.

    Uncover how Haemonetics' forecasts yield a $86.90 fair value, a 52% upside to its current price.

    Exploring Other Perspectives

    HAE 1-Year Stock Price Chart
    HAE 1-Year Stock Price Chart

    Before this setback, the most optimistic analysts were modeling around US$1.6 billion of revenue and nearly US$297 million of earnings by 2028, so if you believed that outlook, this latest loss tests your confidence in that optimism and in whether dependence on a few U.S. products might eventually cap the story.

    Explore 2 other fair value estimates on Haemonetics - why the stock might be worth just $86.90!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Interested In Other Possibilities?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.